IBDEI156 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19071,0)
 ;;=Z84.81^^94^917^29
 ;;^UTILITY(U,$J,358.3,19071,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19071,1,3,0)
 ;;=3^Family Hx of Genetic Disease
 ;;^UTILITY(U,$J,358.3,19071,1,4,0)
 ;;=4^Z84.81
 ;;^UTILITY(U,$J,358.3,19071,2)
 ;;=^5063392
 ;;^UTILITY(U,$J,358.3,19072,0)
 ;;=Z86.010^^94^917^76
 ;;^UTILITY(U,$J,358.3,19072,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19072,1,3,0)
 ;;=3^Personal Hx of Colonic Polyps
 ;;^UTILITY(U,$J,358.3,19072,1,4,0)
 ;;=4^Z86.010
 ;;^UTILITY(U,$J,358.3,19072,2)
 ;;=^5063456
 ;;^UTILITY(U,$J,358.3,19073,0)
 ;;=Z86.14^^94^917^81
 ;;^UTILITY(U,$J,358.3,19073,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19073,1,3,0)
 ;;=3^Personal Hx of MRSA Infection
 ;;^UTILITY(U,$J,358.3,19073,1,4,0)
 ;;=4^Z86.14
 ;;^UTILITY(U,$J,358.3,19073,2)
 ;;=^5063464
 ;;^UTILITY(U,$J,358.3,19074,0)
 ;;=Z86.31^^94^917^77
 ;;^UTILITY(U,$J,358.3,19074,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19074,1,3,0)
 ;;=3^Personal Hx of Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,19074,1,4,0)
 ;;=4^Z86.31
 ;;^UTILITY(U,$J,358.3,19074,2)
 ;;=^5063467
 ;;^UTILITY(U,$J,358.3,19075,0)
 ;;=Z86.711^^94^917^107
 ;;^UTILITY(U,$J,358.3,19075,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19075,1,3,0)
 ;;=3^Personal Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,19075,1,4,0)
 ;;=4^Z86.711
 ;;^UTILITY(U,$J,358.3,19075,2)
 ;;=^5063474
 ;;^UTILITY(U,$J,358.3,19076,0)
 ;;=Z86.72^^94^917^113
 ;;^UTILITY(U,$J,358.3,19076,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19076,1,3,0)
 ;;=3^Personal Hx of Thrombophlebitis
 ;;^UTILITY(U,$J,358.3,19076,1,4,0)
 ;;=4^Z86.72
 ;;^UTILITY(U,$J,358.3,19076,2)
 ;;=^5063476
 ;;^UTILITY(U,$J,358.3,19077,0)
 ;;=Z87.310^^94^917^105
 ;;^UTILITY(U,$J,358.3,19077,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19077,1,3,0)
 ;;=3^Personal Hx of Osteoporosis Fx
 ;;^UTILITY(U,$J,358.3,19077,1,4,0)
 ;;=4^Z87.310
 ;;^UTILITY(U,$J,358.3,19077,2)
 ;;=^5063485
 ;;^UTILITY(U,$J,358.3,19078,0)
 ;;=Z87.442^^94^917^116
 ;;^UTILITY(U,$J,358.3,19078,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19078,1,3,0)
 ;;=3^Personal Hx of Urinary Calculi
 ;;^UTILITY(U,$J,358.3,19078,1,4,0)
 ;;=4^Z87.442
 ;;^UTILITY(U,$J,358.3,19078,2)
 ;;=^5063497
 ;;^UTILITY(U,$J,358.3,19079,0)
 ;;=Z87.81^^94^917^114
 ;;^UTILITY(U,$J,358.3,19079,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19079,1,3,0)
 ;;=3^Personal Hx of Traumatic Fx (Healed)
 ;;^UTILITY(U,$J,358.3,19079,1,4,0)
 ;;=4^Z87.81
 ;;^UTILITY(U,$J,358.3,19079,2)
 ;;=^5063513
 ;;^UTILITY(U,$J,358.3,19080,0)
 ;;=Z87.890^^94^917^109
 ;;^UTILITY(U,$J,358.3,19080,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19080,1,3,0)
 ;;=3^Personal Hx of Sex Reassignment
 ;;^UTILITY(U,$J,358.3,19080,1,4,0)
 ;;=4^Z87.890
 ;;^UTILITY(U,$J,358.3,19080,2)
 ;;=^5063517
 ;;^UTILITY(U,$J,358.3,19081,0)
 ;;=Z87.892^^94^917^74
 ;;^UTILITY(U,$J,358.3,19081,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19081,1,3,0)
 ;;=3^Personal Hx of Anaphylaxis
 ;;^UTILITY(U,$J,358.3,19081,1,4,0)
 ;;=4^Z87.892
 ;;^UTILITY(U,$J,358.3,19081,2)
 ;;=^5063519
 ;;^UTILITY(U,$J,358.3,19082,0)
 ;;=Z87.39^^94^917^102
 ;;^UTILITY(U,$J,358.3,19082,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19082,1,3,0)
 ;;=3^Personal Hx of Musculoskeletal/Connective Tissue Disease
 ;;^UTILITY(U,$J,358.3,19082,1,4,0)
 ;;=4^Z87.39
 ;;^UTILITY(U,$J,358.3,19082,2)
 ;;=^5063488
 ;;^UTILITY(U,$J,358.3,19083,0)
 ;;=Z87.820^^94^917^111
 ;;^UTILITY(U,$J,358.3,19083,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19083,1,3,0)
 ;;=3^Personal Hx of TBI
 ;;^UTILITY(U,$J,358.3,19083,1,4,0)
 ;;=4^Z87.820
 ;;^UTILITY(U,$J,358.3,19083,2)
 ;;=^5063514
